Dr Jeff Sharman from the Willamette Valley Cancer Institute and Research Center discusses clinical trials evaluating the use of Bruton tyrosine kinase inhibitors as treatment for patients with SARS-CoV-2.
Additional Resources
Roschewski M et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunol 2019;5(48):eabd0110. Abstract (https://immunology.sciencemag.org/content/5/48/eabd0110)
AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 [press release (https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html)]. April 14, 2020.
Chong EA et al. BTK inhibitors in cancer patients with COVID19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte). Clin Cancer Res 2020;[Published OnlineFirst]. Abstract (https://clincancerres.aacrjournals.org/content/early/2020/04/28/1078-0432.CCR-20-1427)
COVID-19 and CLL: Frequently Asked Questions. Hematology.org (https://www.hematology.org/covid-19/covid-19-and-cll). May 6, 2020;Version 1.3.
Mehta P et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229);1033-4. Correspondence (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/fulltext)
Koffman B et al. Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol 2020;[Epub ahead of print]. Correspondence (https://onlinelibrary.wiley.com/doi/10.1002/ajh.25851)
Treon ST et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood 2020;135(21):1912–5. Full text (https://ashpublications.org/blood/article/135/21/1912/454437/The-BTK-inhibitor-ibrutinib-may-protect-against)